1,1'-bicyclooctyl-2,2'-dione | 54380-59-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,1'-bicyclooctyl-2,2'-dione
• 英文别名: -2,2'-dion；bicyclooctanedione；2-(2-Oxocyclooctyl)cyclooctan-1-one
• CAS: 54380-59-5
• 化学式: C₁₆H₂₆O₂
• 分子量: 250.381
• InChiKey: YQEBTDUBMOYQTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,1'-bicyclooctyl-2,2'-dione 在 samarium diiodide 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以48%的产率得到(6aR,6bS,12aR,12bR)-Tetradecahydro-cyclobuta[1,2:3,4]dicyclooctene-6a,6b-diol
  参考文献：
  名称：

  io二碘化物介导的1,4-二酮-I的松酸酯化。稠合的单，双和三环环丁烷-1,2-二醇的立体选择性合成

  摘要：

  标题反应已经以良好的产率应用于各种顺式-环丁烷-1,2-二醇的合成中。

  DOI：

  10.1016/0040-4020(96)00687-4
• 作为产物：
  描述：

  1-ethoxycyclooctene 生成 1,1'-bicyclooctyl-2,2'-dione
  参考文献：
  名称：

  Koch,D. et al., Chemische Berichte, 1974, vol. 107, p. 3640 - 3657

  摘要：

  DOI：

文献信息

• Substituted bicyclic derivatives for treating central nervous system disorders
  申请人：——

  公开号：US20020019401A1

  公开（公告）日：2002-02-14

  The present invention relates to compounds of the formula 1 and the pharmaceutically acceptable salts and solvates thereof wherein X 1 , X 2 , X 3 , R 1 , R 2 , R 3 and R 4 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods of treating shizophrenic and shizo-affective disorders, and related disorders which may be treated by administering compounds having dopaminergic activity such as the above compounds of formula 1.

  本发明涉及具有以下通式的化合物，以及其中X1、X2、X3、R1、R2、R3和R4按本发明定义的药用可接受盐和溶剂化物。本发明还涉及包含上述化合物的药物组合物，以及使用上述通式1的化合物治疗精神分裂症、分裂情感障碍和相关障碍的方法，这些化合物具有多巴胺活性。
• Method for producing bicyclic 1,3-diketones
  申请人：——

  公开号：US20030187290A1

  公开（公告）日：2003-10-02

  A process for preparing bicyclic 1,3-diketones of the formula I 1 where R 1 , R 2 , R 3 and R 4 are hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy-carbonyl, halogen, cyano, nitro, C 1 -C 4 -alkylthio, C 1 -C 4 -alkylsulfenyl or C 1 -C 4 -alkylsulfonyl and Z is C 1 -C 4 -alkylene, O, S, N—R 5 where R 5 is C 1 -C 4 -alkyl or C 1 -C 4 -alkylcarbonyl, which comprises a) reacting a bicyclic olefin of the formula II with haloform in the presence of a base to give the ring-expanded product of the formula III 2 where R 1 -R 4 and Z are as defined above and X is halogen; b) hydrolyzing the allylic halogen of the compound of the formula III to the allyl alcohol of the formula IV 3 c) oxidizing the allyl alcohol of the formula IV to the unsaturated ketone of the formula V 4 d) reacting the ketone of the formula V with a nucleophilic ion Y − which stabilizes a negative charge to give the ketone of the formula VI 5 e) hydrolyzing the ketone of the formula VI to the bicyclic 1,3 -diketone of the formula I, novel intermediates and novel processes for preparing these intermediates are described.

  一种制备公式I1中R1、R2、R3和R4为氢、C1-C4烷基、C1-C4烷氧羰基、卤素、氰基、硝基、C1-C4烷基硫基、C1-C4烷基烯基或C1-C4烷基磺酰基，Z为C1-C4烷基亚甲基、氧、硫或N-R5，其中R5为C1-C4烷基或C1-C4烷基羰基的双环1,3-二酮的方法，包括a)在碱存在下，将公式II的双环烯烃与卤代甲烷反应，得到公式III的环扩展产物，其中R1-R4和Z如上定义，X为卤素；b)将公式III化合物的烯丙基卤素水解为公式IV的烯丙醇；c)将公式IV的烯丙醇氧化为公式V的不饱和酮；d)将公式V的酮与稳定负电荷的亲核离子Y-反应，得到公式VI的酮；e)将公式VI的酮水解为公式I的双环1,3-二酮。描述了新的中间体和制备这些中间体的新方法。
• [4.2.0]bicyclooctane derivatives, process for their preparation and pharmaceutical compositions containing same
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0196617A1

  公开（公告）日：1986-10-08

  Compounds useful in treating cardiovascular disorders' such as thrombosis, hypertension, and atherosclerosis are compounds depicted in formulas (1), (2), and (3): wherein: n is 2 or 3; R1 is CH20H, CHO, CO2R or CO2H; R2 is hydrogen or methyl; and R3 is linear or branched alkyl having 5-10 carbon atoms, optionally substituted with lower alkyl, lower alkoxy, trifluoromethyl, or halogen, in which a is 0, 1 or 2; b is 3-7; m is 0, 1 or 2; and or in which R4 is independently hydrogen or lower alkyl having 1-6 carbon atoms; and the pharmaceutically acceptable, non-toxic salts and esters thereof.

  用于治疗心血管疾病如血栓形成、高血压和动脉粥样硬化的化合物是式 (1)、(2) 和 (3) 所示的化合物：其中：n 是 2 或 3；R1 是 CH20H、CHO、CO2R 或 CO2H；R2 是氢或甲基；R3 是具有 5-10 个碳原子的直链或支链烷基，可任选被低级烷基、低级烷氧基、三氟甲基或卤素取代，其中 a 是 0、1 或 2；b 是 3-7；m 是 0、1 或 2；或 R4 独立地是氢或具有 1-6 个碳原子的低级烷基；以及它们的药学上可接受的无毒盐和酯。
• Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity
  申请人：Pfizer Products Inc.

  公开号：EP0953567A2

  公开（公告）日：1999-11-03

  The present invention relates to compounds of the formula each dashed line in the above formula represents an optional double bond, provided both dashed lines do not simultaneously represent a double bond; X1 and X2 are each independently selected from O and -(CH2)j- wherein j is 1 or 2, provided that no O is doubly-bonded to an adjacent atom; X3 is -CH(R5)N(R8)CH(R6)-, -CH(R5)C(R8)(R9)CH(R5)-, -C(R5)=C(R8)CH(R6)-, or -CH(R5)C(R8)=C(R6)-; R1 and R2 are each independently H, hydroxy, or C1-C6alkyl; or R1 and R2 are taken together as a bond; each R3 is independently selected from -S(O)jF7 wherein j is an integer ranging from 0 to 2, -C(O)R7, -OR7, -NC(O)R7, -NR7R12, and the substituents provided in the definition of R7 other than H; R4 is absent where the dashed line in the above formula 1 represents a double bond or R4 is selected from H and the substituents provided in the definition of R3; or R3 and R4 are taken together with the carbon atom to which each is attached to form a 5-10 membered mono-cyclic or bicyclic group wherein said cyclic group may be carbocyclic or heterocyclic with 1 to 3 heteroatoms selected from O, S, and -N(R11)- with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; said cyclic group is saturated or partially unsaturated; aromatic or non-aromatic; 1 or 2 of the carbon atoms in said cyclic group optionally may be replaced by an oxo -C(O)- moiety; and said cyclic group is optionally substituted by 1 to 3 R10 groups. The invention also relates to pharmaceutical compositions containing the above compounds and to methods of treating shizophrenic and shizo-affective disorders, and related disorders which may be treated by administering compounds having dopaminergic activity such as the above compounds of formula 1.

  本发明涉及如下式的化合物 上式中的每条虚线代表一个任选双键，条件是两条虚线不同时代表一个双键； X1和X2各自独立地选自O和-(CH2)j-，其中j为1或2，条件是没有O与相邻原子成双键； X3 是-CH(R5)N(R8)CH(R6)-、-CH(R5)C(R8)(R9)CH(R5)-、-C(R5)＝C(R8)CH(R6)-或-CH(R5)C(R8)＝C(R6)-； R1 和 R2 各自独立地为 H、羟基或 C1-C6 烷基； 或 R1 和 R2 合在一起为键； 每个 R3 独立地选自-S(O)jF7（其中 j 为 0 至 2 的整数）、-C(O)R7、-OR7、-NC(O)R7、-NR7R12 和 R7 定义中提供的除 H 以外的取代基； R4 不存在，其中上式 1 中的虚线代表双键，或者 R4 选自 H 和 R3 定义中提供的取代基； 或 R3 和 R4 与各自所连接的碳原子一起形成 5-10 个成员的单环或双环基团，其中所述环基可以是碳环或杂环，带有 1 至 3 个选自 O、S 和-N(R11)-的杂原子，但两个 O 原子、两个 S 原子或一个 O 原子和一个 S 原子之间不能直接连接；所述环状基团是饱和的或部分不饱和的；芳香的或非芳香的；所述环状基团中的 1 个或 2 个碳原子可选择性地被氧代-C(O)-分子取代；所述环状基团可选择性地被 1 至 3 个 R10 基团取代。 本发明还涉及含有上述化合物的药物组合物和治疗精神分裂症和精神情感障碍的方法，以及可通过施用具有多巴胺能活性的化合物（如上述式 1 化合物）来治疗的相关障碍。
• Verfahren zur katalytischen Oxidation von 1,5-Dialkylbicyclo(3.2.1)octan-8-ol zu 1,5-Diaklylbicyclo(3.2.1)octan-8-on
  申请人：Aventis Research & Technologies GmbH & Co. KG

  公开号：EP0979810A1

  公开（公告）日：2000-02-16

  Verfahren zur Herstellung von Bicyclooctanon insbesondere 1,5-Dialkylbicyclo(3.2.1)octan-8-on durch Umsetzung von Bicyclooctanol insbesondere Dialkylbicyclo(3.2.1)octan-8-ol mit a. einem auf einem Aktivkohleträger aufgebrachten Katalysator enthaltend Heteropolyoxometallatanionen von Vanadium, Molybdän und Phosphor sowie ein entsprechendes Alkali-, Erdalkali- und/oder Ammonium-Gegenion und b. einem gasförmigen, sauerstoffhaltigen Oxidationsmittel

  通过使双环辛醇，特别是二烷基双环(3.2.1)辛烷-8-醇与下列物质反应制备双环辛酮，特别是 1,5-二烷基双环(3.2.1)辛烷-8-酮的工艺过程 a. 一种应用于活性碳载体的催化剂，该载体含有钒、钼和磷的杂多氧金属阴离子以及相应的碱金属、碱土金属和/或铵反离子，以及 b. 气体含氧氧化剂